Clinical trial

Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options

Name
F901318/0032
Description
A study to evaluate F901318 (study drug) for the treatment of invasive fungal infections in patients lacking suitable alternative treatment options.
Trial arms
Trial start
2018-06-06
Estimated PCD
2022-09-02
Trial end
2023-04-01
Status
Recruiting
Phase
Early phase I
Treatment
F901318
30mg tablets with a maximum daily dose of 300mg with dose adjustments according to plasma levels of F901318 and concomitant treatment with CYP inducers or inhibitors
Arms:
F901318
Size
200
Primary endpoint
DRC adjudicated overall response at Day 42 using a combination of clinical, mycological and radiological response
Day 42
Eligibility criteria
Inclusion Criteria: * Male and female aged at least 18 years, or male and female aged 16 years or 17 years and who weigh at least 40 kg whom have given informed consent * Ability and willingness to comply with the protocol. * Able to take oral medication * Female must be non-lactating and at no risk of pregnancy * Male with female partners of childbearing potential must either abstain from sexual intercourse or use a highly effective means of contraception * Patients with invasive fungal disease * Patients who have limited alternative treatment options Exclusion Criteria: * Women who are pregnant or breastfeeding. * Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug. * Patients with chronic aspergillosis, aspergilloma or allergic bronchopulmonary aspergillosis. * HIV infection but not currently receiving antiretroviral therapy. * Patients with a medical condition that may jeopardize adherence to the protocol or may cause unacceptable additional risk to the patient * Previously enrolled patients or patients enrolled in any clinical trial within the last 30 days * Patients receiving treatment limited to supportive care due to predicted short survival time. * Prohibited concomitant medications. * Any exclusion criteria required by local regulatory authorities.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}
Updated at
2022-12-01

1 organization

1 product

1 indication

Product
F901318
Organization
F2G Biotech